US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Invesco Dorsey Wright Healthcare Momentum ETF

61.36

-0.0859-0.14%

Volume:17.68K

Turnover:1.08M

Market Cap:271.23M

PE:20.07

High:61.36

Open:61.16

Low:60.67

Close:61.45

52wk High:64.10

52wk Low:39.36

Shares:4.42M

Float Shares:4.42M

Volume Ratio:0.27

T/O Rate:0.40%

Dividend:1.53

Dividend Rate:2.49%

EPS(TTM):3.06

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Axsome COO Mark Jacobson Sells 10,000 Shares for $2.09 Million

Immunovant Holds Annual Stockholder Meeting with 96% Shares Represented

Analysts Are Bullish on Top Healthcare Stocks: Revolution Medicines (RVMD), Teva Pharmaceutical (TEVA)

Yinchuan Market Regulators Roll Out Comprehensive Measures to Implement Revised Medical Device Production Quality Standards

Buy Rating Reiterated on Daraxonrasib Strength, RASolve 301 Upsizing, and Unchanged $315 Price Target

NEJM publishes Phase 1/2 clinical data on daraxonrasib

New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer

Revolution Medicines Director Lorence H. Kim Disposes of Common Shares Worth $11.21 Million

Shenzhen Regulator Launches 2026 Roadshow Selection for Key Medical Device Innovation Projects

Axsome Therapeutics to Participate in Upcoming Investor Conferences

Guardant Health Price Target Maintained with a $195.00/Share by BTIG

Shinva Medical Secures Class II and III Device Approvals for Advanced Radiotherapy and Thoracoscopic Systems

港股动态：今海医疗科技股价攀升逾4%，中期收益激增逾1.3倍，核心业务向高附加值医疗器械领域转型

Roivant Sciences President, Immunovant CEO Eric Venker Disposes of Common Shares Worth $7.15 Million

Analysts Are Bullish on Top Healthcare Stocks: Medtronic (MDT), Guardant Health (GH)

Guardant Health Shield Blood Test Wins Carelon Coverage for Colorectal Cancer Screening

Tellgen Corporation Secures Six New Medical Device Approvals

Medical Sector Hitting an Earnings Inflection Point? 512170 Ends Green Amid AI4S Boost for HK CXO Stocks

Revolution Medicines Signs Long-Term Headquarters Lease Agreement

Revolution Medicines (RVMD) Could Be 7% Below Fair Value On FDA Approval Of RASONQUE

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/stock/PTH/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PTH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTH\",,,,,undefined,":{"symbol":"PTH","market":"US","secType":"STK","nameCN":"Invesco Dorsey Wright Healthcare Momentum ETF","latestPrice":61.3641,"timestamp":1788465600000,"preClose":61.45,"halted":0,"volume":17681,"delay":0,"changeRate":-0.0013978844589097202,"floatShares":4420000,"shares":4420000,"eps":3.057033,"marketStatus":"Pre-Mkt","change":-0.0859,"latestTime":"09-04 08:43:06 EDT","open":61.16,"high":61.3641,"low":60.67,"amount":1081121.276735,"amplitude":0.011295,"askPrice":69.83,"askSize":100,"bidPrice":54.21,"bidSize":100,"shortable":3,"etf":1,"ttmEps":3.057033,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788528600000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":61.3641,"sharesOutstanding":2480000,"nav":61.35956,"aum":274890828.8,"dividendRate":0.024879,"bidAskSpread":0.001745,"postHourTrading":{"tag":"盘后","latestPrice":61.35,"preClose":61.3641,"latestTime":"19:30 EDT","volume":11,"amount":675.5846,"timestamp":1788478205997,"change":-0.0141,"changeRate":-0.00023,"amplitude":0},"volumeRatio":0.2660621425403068,"impliedVol":0.1181,"impliedVolPercentile":0.4701},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTH\",,,,,undefined,":{"symbol":"PTH","floatShares":4420000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.2660621425403068,"shares":4420000,"dividePrice":1.5267,"high":61.3641,"amplitude":0.011295,"preClose":61.45,"low":60.67,"week52Low":39.36,"pbRate":"--","week52High":64.1,"institutionHeld":0,"latestPrice":61.3641,"eps":3.057033,"divideRate":0.024879,"volume":17681,"delay":0,"ttmEps":3.057033,"open":61.16,"prevYearClose":49.701,"prevWeekClose":61.0661,"prevMonthClose":60.7941,"prevQuarterClose":59.76,"fiveDayClose":63.5328,"twentyDayClose":58.91,"sixtyDayClose":49.9616},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PTH\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"PTH","amount":1.52645,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"Invesco Dorsey Wright Healthcare Momentum ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2024-06-24","symbol":"PTH","amount":0.02545,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-24","defaultRemindTime":1719235800000,"name":"Invesco Dorsey Wright Healthcare Momentum ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-28","payableDate":"2024-06-24","currency":"USD","dateTimestamp":1719201600000,"payDate":"2024-06-28"},{"market":"US","date":"2023-07-17","symbol":"PTH","defaultRemindTime":1689600600000,"type":"split","dateTimestamp":1689566400000,"forFactor":1,"toFactor":3,"ratio":0.3333333333333333}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PTH\",market:\"US\",,,undefined,":[{"executeDate":"2024-06-24","recordDate":"2024-06-24","paymentDate":"2024-06-28","value":0.02545,"currency":"USD"},{"executeDate":"2025-12-22","recordDate":"2025-12-22","paymentDate":"2025-12-26","value":1.52645,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PTH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PTH\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664802202","title":"Axsome COO Mark Jacobson Sells 10,000 Shares for $2.09 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2664802202","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664802202?lang=en_us&edition=fundamental","pubTime":"2026-09-04 07:09","pubTimestamp":1788476991,"startTime":"0","endTime":"0","summary":"Axsome COO Mark Jacobson sells 10,000 shares for $2.09 millionAxsome Therapeutics COO Mark L. Jacobson exercised stock options for 10,000 common shares at $12.95 on Sept. 3, 2026.He sold 10,000 common","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDLc9hvxK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Axsome COO Mark Jacobson Sells 10,000 Shares for $2.09 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PTH","AXSM","BK4585","LU2324357040.USD","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664049898","title":"Immunovant Holds Annual Stockholder Meeting with 96% Shares Represented","url":"https://stock-news.laohu8.com/highlight/detail?id=2664049898","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664049898?lang=en_us&edition=fundamental","pubTime":"2026-09-04 05:06","pubTimestamp":1788469582,"startTime":"0","endTime":"0","summary":"Immunovant holds annual stockholder meeting with 96% shares representedImmunovant held its annual shareholder meeting on Sept. 2, 2026.Shareholders backed the selection of Ernst & Young as independent","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDL364hlT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PTH","BK4588","BK4585","BK4007","ROIV","IMVT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664704888","title":"Analysts Are Bullish on Top Healthcare Stocks: Revolution Medicines (RVMD), Teva Pharmaceutical (TEVA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2664704888","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664704888?lang=en_us&edition=fundamental","pubTime":"2026-09-03 22:10","pubTimestamp":1788444623,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Revolution Medicines (RVMD) and Teva Pharmaceutical ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-revolution-medicines-rvmd-teva-pharmaceutical-teva-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-revolution-medicines-rvmd-teva-pharmaceutical-teva-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B2B36J28.USD","IE00BJT1NW94.SGD","LU0029874061.USD","BK4585","IE0002141913.USD","LABU","IE00BFTCPJ56.SGD","BK4588","XLV","LU0128526141.USD","BK4557","IDNA","XBI","HCSG","IE00B4R5TH58.HKD","TEVA","BK4566","LU1983299246.USD","BK4137","BBH","LU2324357040.USD","BK4581","RVMD","IE00BJJMRZ35.SGD","CANC","IE0009354923.USD","BK4007","LU0320765992.SGD","PTH","BK4139","BK4584","LU0109394709.USD","IE0009355771.USD","BK4559","LU0889565916.HKD","BK4596"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121486923","title":"Yinchuan Market Regulators Roll Out Comprehensive Measures to Implement Revised Medical Device Production Quality Standards","url":"https://stock-news.laohu8.com/highlight/detail?id=1121486923","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121486923?lang=en_us&edition=fundamental","pubTime":"2026-09-03 16:00","pubTimestamp":1788422444,"startTime":"0","endTime":"0","summary":"The Yinchuan Municipal Market Supervision Administration in Ningxia is advancing a multi-pronged strategy to ensure the smooth implementation of the newly revised Medical Device Production Quality...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159883","LNGR","GDOC","MEDX","PTH","HART","IEIH","LGHT","BK1574","RSPH","BK1583","09996","AGNG","BK1100","MDEV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664828323","title":"Buy Rating Reiterated on Daraxonrasib Strength, RASolve 301 Upsizing, and Unchanged $315 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2664828323","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664828323?lang=en_us&edition=fundamental","pubTime":"2026-09-03 09:25","pubTimestamp":1788398717,"startTime":"0","endTime":"0","summary":"LifeSci Capital analyst Charles Zhu maintained a Buy rating on Revolution Medicines yesterday and set a price target of $315.00. Charles Zhu has gi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-reiterated-on-daraxonrasib-strength-rasolve-301-upsizing-and-unchanged-315-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-reiterated-on-daraxonrasib-strength-rasolve-301-upsizing-and-unchanged-315-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0889565916.HKD","IE0009354923.USD","IE0002141913.USD","LU0320765992.SGD","BBH","IE00BFTCPJ56.SGD","LU0109394709.USD","IDNA","BK4139","IE00B2B36J28.USD","IE00B4R5TH58.HKD","PTH","RVMD","IE0009355771.USD","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","CANC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664844659","title":"NEJM publishes Phase 1/2 clinical data on daraxonrasib","url":"https://stock-news.laohu8.com/highlight/detail?id=2664844659","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664844659?lang=en_us&edition=fundamental","pubTime":"2026-09-03 05:55","pubTimestamp":1788386116,"startTime":"0","endTime":"0","summary":"Revolution Medicines (RVMD) “announced that The New England Journal of Medicine has published a report describing data from the Phase 1/2 clinical ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nejm-publishes-phase-1-2-clinical-data-on-daraxonrasib-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nejm-publishes-phase-1-2-clinical-data-on-daraxonrasib-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BJJMRZ35.SGD","BK4139","LU0320765992.SGD","CANC","IE00B4R5TH58.HKD","IE0009354923.USD","IE0009355771.USD","BBH","PTH","RVMD","IE00BFTCPJ56.SGD","LU0109394709.USD","IE0002141913.USD","IE00B2B36J28.USD","LU0889565916.HKD","IDNA","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664844613","title":"New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2664844613","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664844613?lang=en_us&edition=fundamental","pubTime":"2026-09-03 05:50","pubTimestamp":1788385800,"startTime":"0","endTime":"0","summary":"Results support the clinical rationale for RASolve 301, an ongoing Phase 3 trial in RAS mutant metastatic non-small cell lung cancer REDWOOD CITY, Calif., Sept.  02, 2026 (GLOBE NEWSWIRE) --  Revoluti","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/02/3355564/0/en/new-england-journal-of-medicine-publishes-phase-1-2-clinical-data-on-revolution-medicines-rasonque-daraxonrasib-in-metastatic-non-small-cell-lung-cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDOC","IE00BFMHRM44.USD","ONX","IE00B2B36J28.USD","CANC","RVMD","IE0009355771.USD","LU2360107325.USD","IE00BFTCPJ56.SGD","LU1548497426.USD","L","LU1861219969.SGD","IE00B4R5TH58.HKD","BK4107","IE00BJJMRZ35.SGD","LU0124384867.USD","LU0320765992.SGD","ON","IE0002141913.USD","LU1861220033.SGD","BK4588","BK4141","NVIB","IE00BJT1NW94.SGD","BMED","LU2298322129.HKD","IE00BD6J9T35.USD","BBH","LU1854104046.USD","IE00BZ199S13.USD","IE0009354923.USD","BK4139","LU1720051017.SGD","LU2357305700.SGD","LU0348723411.USD","LU1861215975.USD","ONG","LU0724618433.USD","LU0053666078.USD","BK4605","LU0889565916.HKD","LU2487616109.SGD","LU1983260115.SGD","PTH","BK4512","LU1978683503.SGD","BK4585","IDNA","LU0109394709.USD","LU1854103824.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664984906","title":"Revolution Medicines Director Lorence H. Kim Disposes of Common Shares Worth $11.21 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2664984906","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664984906?lang=en_us&edition=fundamental","pubTime":"2026-09-03 04:31","pubTimestamp":1788381115,"startTime":"0","endTime":"0","summary":"Revolution Medicines director Lorence H. Kim disposes of common shares worth $11.21 millionRevolution Medicines director Lorence H. Kim sold 56,000 common shares on Aug. 31 at about $200.56–$206.15.Sa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDL1bnXL6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Revolution Medicines Director Lorence H. Kim Disposes of Common Shares Worth $11.21 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDNA","BK4139","LU0109394709.USD","IE00BJT1NW94.SGD","IE0002141913.USD","CANC","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","RVMD","IE0009354923.USD","IE00BJJMRZ35.SGD","IE0009355771.USD","LU0320765992.SGD","LU0889565916.HKD","PTH","IE00B2B36J28.USD","BBH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149967319","title":"Shenzhen Regulator Launches 2026 Roadshow Selection for Key Medical Device Innovation Projects","url":"https://stock-news.laohu8.com/highlight/detail?id=1149967319","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149967319?lang=en_us&edition=fundamental","pubTime":"2026-09-02 19:44","pubTimestamp":1788349448,"startTime":"0","endTime":"0","summary":"To advance high-quality development in the medical device industry and uncover promising local innovations, the Shenzhen Municipal Market Supervision Administration recently organized a roadshow and...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1100","159883","BK1583","IEIH","PTH","HART","MEDX","GDOC","LGHT","BK1574","LNGR","MDEV","RSPH","AGNG","09996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664815725","title":"Axsome Therapeutics to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2664815725","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664815725?lang=en_us&edition=fundamental","pubTime":"2026-09-02 19:00","pubTimestamp":1788346800,"startTime":"0","endTime":"0","summary":"NEW YORK, Sept.  02, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/02/3354987/33090/en/axsome-therapeutics-to-participate-in-upcoming-investor-conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2028103732.USD","BK4516","LU1363072403.SGD","LU0912757837.SGD","BK4504","LU0234570918.USD","LU1989772923.USD","LU0225283273.USD","LU0320765646.SGD","LU2089283258.USD","LU2264538146.SGD","PTH","CNS","LU0106831901.USD","LU0882574139.USD","LU0210528500.USD","LU2324357040.USD","LU2023251221.USD","LU1548497426.USD","BK4585","LU0267386448.USD","IE00B3S45H60.SGD","LU0795875169.SGD","LU1732800096.USD","LU0158827781.USD","LU2111349929.HKD","BK4135","AXSM","LU0006306889.USD","LU0971096721.USD","IE00BZ1G4Q59.USD","LU1162221912.USD","IAI","LU1732799900.SGD","LU0098860793.USD","KBWB","BK4588","LU0158827948.USD","BK4534","LU0557290698.USD","LU1668664300.SGD","LU0390134368.USD","LU1064131342.USD","BK4127","LU1244550577.SGD","BK4581","BK4007","LU1720051108.HKD","IE00B775SV38.USD","LU2487616109.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664818611","title":"Guardant Health Price Target Maintained with a $195.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2664818611","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664818611?lang=en_us&edition=fundamental","pubTime":"2026-09-02 17:52","pubTimestamp":1788342720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GH/analyst-ratings","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","BK4551","BK4585","PTH","BK4588","BK4196","HELX","GNMX","LFSC","GNOM","GH","FFOX","GDOC","LU0320765992.SGD","LU0889565916.HKD","EKG","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186287506","title":"Shinva Medical Secures Class II and III Device Approvals for Advanced Radiotherapy and Thoracoscopic Systems","url":"https://stock-news.laohu8.com/highlight/detail?id=1186287506","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186287506?lang=en_us&edition=fundamental","pubTime":"2026-09-02 15:51","pubTimestamp":1788335497,"startTime":"0","endTime":"0","summary":"Shinva Medical Instrument Co.,Ltd. (600587.SH) has announced that it recently received the Medical Device Registration Certificate from China's National Medical Products Administration, while its...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGNG","600587","LGHT","MDEV","IEIH","BK1583","LNGR","BK0188","HART","159883","BK1100","RSPH","GDOC","BK1574","PTH","MEDX","BK0251","09996","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184201272","title":"港股动态：今海医疗科技股价攀升逾4%，中期收益激增逾1.3倍，核心业务向高附加值医疗器械领域转型","url":"https://stock-news.laohu8.com/highlight/detail?id=1184201272","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184201272?lang=en_us&edition=fundamental","pubTime":"2026-09-02 14:10","pubTimestamp":1788329416,"startTime":"0","endTime":"0","summary":"今海医疗科技（02225）股价今日表现活跃，盘中涨幅一度超过5%。截至最新交易时段，该股上涨4.08%，报4.72港元，成交额达628.74万港元。据近期披露的2026年中期业绩显示，公司在营收扩张与盈利质量方面均呈现积极态势。报告期内，集团实现收益3402.1万新加坡元，较去年同期大幅增长134.16%，彰显出强劲的销售增长动能。从业务结构来看，2026年上半年，公司收入构成实现显著优化，战略重...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","159883","MDEV","MEDX","LGHT","BK1574","BK1583","02225","VXUS","HART","BK1100","LNGR","09996","AGNG","RSPH","BK1150","IEIH","PTH","KCAI","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664125867","title":"Roivant Sciences President, Immunovant CEO Eric Venker Disposes of Common Shares Worth $7.15 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2664125867","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664125867?lang=en_us&edition=fundamental","pubTime":"2026-09-02 09:01","pubTimestamp":1788310876,"startTime":"0","endTime":"0","summary":"Roivant Sciences President, Immunovant CEO Eric Venker disposes of common shares worth $7.15 millionRoivant Sciences President and Immunovant CEO Eric Venker cut his stake to 1,599,154 common shares o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDL1wcvb5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","BK4588","ROIV","IMVT","BK4585","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664863257","title":"Analysts Are Bullish on Top Healthcare Stocks: Medtronic (MDT), Guardant Health (GH)","url":"https://stock-news.laohu8.com/highlight/detail?id=2664863257","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664863257?lang=en_us&edition=fundamental","pubTime":"2026-09-02 01:40","pubTimestamp":1788284405,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Medtronic (MDT) and Guardant Health (GH) with bullis...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-medtronic-mdt-guardant-health-gh-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-medtronic-mdt-guardant-health-gh-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GNOM","IE00BQXX3C00.GBP","LU0208291251.USD","MDT","BK4535","LU1983299246.USD","LU1989771016.USD","LU2271345857.HKD","LU0072461881.USD","LU0211326755.USD","LU1506573853.SGD","LU1989764748.USD","IE00B3PB1722.GBP","LU2089283258.USD","PTH","LU0029874061.USD","LU0211331839.USD","LU1116320737.USD","LU0162691827.USD","LU0976567544.SGD","GH","LU0265550946.USD","LU0109394709.USD","LU0889565916.HKD","IE00BQXX3F31.USD","LU1061106388.HKD","GDOC","LU2023251221.USD","LU1244550221.USD","LABU","EKG","HELX","LU0106261372.USD","XLV","XBI","GNMX","IE000M9KFDE8.USD","IE00BFXG1179.USD","LFSC","LU0432979614.USD","LU1291159041.SGD","LU2089284900.SGD","BK4082","FFOX","HCSG","LU0320765489.SGD","LU1571399168.USD","LU2028103732.USD","LU0128526141.USD","LU0158827781.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664856780","title":"Guardant Health Shield Blood Test Wins Carelon Coverage for Colorectal Cancer Screening","url":"https://stock-news.laohu8.com/highlight/detail?id=2664856780","media":"Reuters","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664856780?lang=en_us&edition=fundamental","pubTime":"2026-09-01 20:06","pubTimestamp":1788264367,"startTime":"0","endTime":"0","summary":"Guardant Health Shield blood test wins Carelon coverage for colorectal cancer screeningGuardant Health secured Carelon Healthcare Services coverage for its FDA-approved Shield blood test for colorecta","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nNDL9hPZ6Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","GNMX","LFSC","LU0320765992.SGD","BK4585","BK4551","FFOX","GDOC","LU0109394709.USD","BK4588","HELX","GNOM","LU0889565916.HKD","EKG","BK4196","GH","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157462487","title":"Tellgen Corporation Secures Six New Medical Device Approvals","url":"https://stock-news.laohu8.com/highlight/detail?id=1157462487","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157462487?lang=en_us&edition=fundamental","pubTime":"2026-09-01 19:36","pubTimestamp":1788262589,"startTime":"0","endTime":"0","summary":"Tellgen Corporation (300642.SZ) has announced that the company and its controlling subsidiary, Shanghai Maishi Biotechnology Co., Ltd., recently obtained six medical device registration certificates...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGNG","LGHT","MDEV","300642","IEIH","BK1583","LNGR","BK0042","HART","BK0239","159883","BK1100","RSPH","GDOC","BK0046","BK1574","PTH","MEDX","09996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141380242","title":"Medical Sector Hitting an Earnings Inflection Point? 512170 Ends Green Amid AI4S Boost for HK CXO Stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=1141380242","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141380242?lang=en_us&edition=fundamental","pubTime":"2026-09-01 19:20","pubTimestamp":1788261656,"startTime":"0","endTime":"0","summary":"On September 1st, medical stocks in both A-shares and Hong Kong markets bucked the market's downbeat trend, with related products such as Medical ETF Huabao (512170) and HK Stock Connect Medical ETF...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1100","WX","CXO","BK1583","IEIH","LNGR","KCAI","FLHK","159883","HART","LGHT","PTH","09996","AGNG","MDEV","MEDX","BK1574","BK4585","GDOC","BK4588","VXUS","RSPH","512170"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664538548","title":"Revolution Medicines Signs Long-Term Headquarters Lease Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2664538548","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664538548?lang=en_us&edition=fundamental","pubTime":"2026-09-01 18:29","pubTimestamp":1788258558,"startTime":"0","endTime":"0","summary":"Revolution Medicines ( ($RVMD) ) has provided an announcement. On August 27, 2026, Revolution Medicines agreed to lease four buildings totaling abo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/revolution-medicines-signs-long-term-headquarters-lease-agreement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/revolution-medicines-signs-long-term-headquarters-lease-agreement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CANC","IDNA","IE00B2B36J28.USD","BBH","LU0889565916.HKD","IE0009354923.USD","BK4139","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","LU0109394709.USD","PTH","RVMD","IE0002141913.USD","LU0320765992.SGD","IE0009355771.USD","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664883781","title":"Revolution Medicines (RVMD) Could Be 7% Below Fair Value On FDA Approval Of RASONQUE","url":"https://stock-news.laohu8.com/highlight/detail?id=2664883781","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664883781?lang=en_us&edition=fundamental","pubTime":"2026-09-01 16:22","pubTimestamp":1788250932,"startTime":"0","endTime":"0","summary":"Revolution Medicines (RVMD) is in focus after the FDA approved RASONQUE, an oral RAS(ON) inhibitor for adults with metastatic pancreatic adenocarcinoma following prior systemic therapy or for those unsuitable for multiagent regimens.\nRevolution Medicines’ share price is around US$205.57 after a slight pullback over the past week. The 30 day share price return of 9.62% and 90 day share price return of 35.86% sit against a year to date share price return of 160.15%, while the 1 year total...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rvmd/revolution-medicines/news/revolution-medicines-rvmd-could-be-7-below-fair-value-on-fda","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rvmd/revolution-medicines/news/revolution-medicines-rvmd-could-be-7-below-fair-value-on-fda","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1861219969.SGD","PTH","ON","ONX","LABU","CANC","BK4605","LU2298322129.HKD","LU2360107325.USD","LU1861214812.USD","LU1720051108.HKD","LU1983260115.SGD","ONG","LU0320765992.SGD","IE0009355771.USD","IE00BFTCPJ56.SGD","BK4139","IE00B2B36J28.USD","LU0889565916.HKD","LU1548497426.USD","IE00BJT1NW94.SGD","LU0109394709.USD","LU1720051017.SGD","LU1861215975.USD","IE00BZ199S13.USD","IE0002141913.USD","IE0009354923.USD","IDNA","IE00BJJMRZ35.SGD","LU1854103824.USD","LU2357305700.SGD","BK4512","BK4585","LU1861220033.SGD","LU0724618433.USD","LU1978683503.SGD","BK4588","IE00BD6J9T35.USD","LU0124384867.USD","LU1854104046.USD","RVMD","IE00BFMHRM44.USD","BK4141","BBH","LU0348723411.USD","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}